PEAQX tetrasodium hydrate

Non Antibodies

NR1, NR2 receptors

Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C

560, 15

An Antagonist of NMDA Receptors

Centrifuge the vial before adding solvent (10, 000 x g for 5 minutes). The lyophilizate may be difficult to visualize. Add solvent directly to the centrifuged vial. Tap the vial to aid in dissolving the lyophilized product. Tilt and gently roll the liquid over the walls of the vial. Avoid vigorous vortexing. Light vortexing for up to 3 seconds is acceptable if needed. Soluble in DMSO. Prepare a concentrated stock solution by dissolving the lyophilized peptide in DMSO first (e.g., at a concentration between 100-1000x of the final working concentration). Once the peptide is completely dissolved in DMSO, slowly dilute the solution into the working buffer (or water) to the desired final working concentration. Centrifuge all product preparations before use. It is recommended to keep the DMSO concentration as low as possible. For cell assays, a final concentration of 0.1%–0.5% DMSO (v/v) is considered safe. For other experiments, a 5% DMSO (v/v) concentration is recommended

41116134

PEAQX is an NMDA receptor antagonist1.

Yes

PEAQX tetrasodium hydrate (NVP-AAM007) is a competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. This compound shows higher selectivity for NR2A over NR2B subunit-containing receptor. PEAQX IC50 values are strongly dependent on agonist concentration used to evoke response. IC50 for NR1/NR2A were 31 ± 2 nM for EC50 of glutamate, and 214 ± 10 nM for 10-times the EC50 of glutamate. IC50 values for NR1/NR2B were significantly higher: 215 ± 13 nM and 2.2 ± 0.14 μM for EC50 and 10-times the EC50 of glutamate, respectively1.Several studies claim that PEAQX has the ability to cause a blockade of adult long-term potentiation while only moderately affecting juvenile long-term potentiation. It was shown that subsaturating concentrations of APV (a NMDAR antagonist) can imitate the effects of PEAQX on long-term potentiation. These findings suggest that the synaptic plasticity affected by PEAQX can be explained by nonspecific blockade of NMDA receptors2.NMDA receptors play an important role in a variety of cellular processes and brain functions such as synaptic plasticity, addiction and stroke. NMDA receptors mediate several physiological functions including learning and memory formation; they play a role in glutamate excitotoxicity and are involved in many neurodegenerative conditions including Alzheimer's disease3.